Current Oncology Reports

, Volume 6, Issue 4, pp 297–304

Management of anemia in patients with cancer

  • David P. Steensma


Anemia is extremely common in patients with cancer. Low hemoglobin levels are associated with diminished quality of life and possibly decreased overall survival. Successful treatment of anemia has undeniable benefits for patients, often yielding dramatic symptomatic improvement that can be very satisfying for clinicians to observe. This review focuses on evolving issues in the management of anemia in patients suffering from cancer. Topics addressed include new evidence-based guidelines concerning the use of epoetin alfa, the evolving role of darbepoetin alfa in cancer-associated anemia, the potential for concomitant iron supplementation to maximize response to erythropoietic agents, the unresolved question of whether erythropoietin use affects survival in cancer patients, new concerns about the risk of thromboembolism in cancer patients with higher hemoglobin levels who are receiving epoetin, and possible immunosuppressive effects of blood product transfusions that may have relevance to neoplasia progression.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Coiffier, B, Guastalla JP, Pujade-Lauraine E, Bastit P, for the Anemia Study Group: Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer 2001, 37:1617–1623.PubMedCrossRefGoogle Scholar
  2. 2.
    Spivak, JL: Cancer-related anemia: its causes and characteristics. Semin Oncol 1994, 21(Suppl 3):3–8.PubMedGoogle Scholar
  3. 3.
    Miller CB, Jones RJ, Piantadosi S, et al.: Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990, 322:1689–1692.PubMedCrossRefGoogle Scholar
  4. 4.
    Cella D: Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998, 25(Suppl 7):43–46.PubMedGoogle Scholar
  5. 5.
    Vogelzang NJ, Breitbard W, Cella D, et al.: Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997, 34(Suppl 2):4–12.PubMedGoogle Scholar
  6. 6.
    Rizzo JD, Lichtin AE, Woolf SH, et al.: Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002, 100:2303–2320.PubMedCrossRefGoogle Scholar
  7. 7.
    Agency for Healthcare Research and Quality (AHRQ): Uses of Epoetin for Anemia in Oncology. Silver Spring, MD: AHRQ; June 2001. Publication number 01-E009. This detailed review is the basis for the ASCO/ASH evidence-based guidelines [6] on appropriate use of epoetin alfa. Although rather conservative, these guidelines represent the de facto standard of care in the United States.Google Scholar
  8. 8.
    Henry DH: Guidelines for the use of epoetin in cancer patients: a much-needed step forward in standardizing anemia treatment. Blood 2003, 102:2697–2698.PubMedCrossRefGoogle Scholar
  9. 9.
    Patrick DL, Gagnon DD, Zagari MJ, et al.: Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003, 39:335–345.PubMedCrossRefGoogle Scholar
  10. 10.
    Cella D, Zagari MJ, Vandoros C, et al.: Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003, 21:366–373.PubMedCrossRefGoogle Scholar
  11. 11.
    Oster W, Herrmann F, Gamm H, et al.: Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 1990, 8:956–962.PubMedGoogle Scholar
  12. 12.
    Ludwig H, Fritz E, Kotzmann H, et al.: Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990, 322:1693–1699.PubMedCrossRefGoogle Scholar
  13. 13.
    Silberstein PT, Witzig TE, Sloan JA, et al.: Weekly erythropoietin for patients with chemotherapy induced anemia: a randomized, placebo-controlled trial in the North Central Cancer Treatment Group [abstract]. Proc ASCO 2002, 21:1422.Google Scholar
  14. 14.
    Seidenfeld J, Piper M, Aronson N: Building the case: What evidence exists for usage of epoetin and how good is the evidence In Hematology 2001: American Society of Hematology Education Program Book. Edited by Schechter GP. Washington, DC: American Society of Hematology; 2001:14–19.Google Scholar
  15. 15.
    Littlewood TJ, Bajetta E: Early administration of epoetin alfa optimizes anemia management with respect to hematologic and quality of life outcomes in anemic cancer patients undergoing chemotherapy [abstract]. Blood 2002, 100:A3524.Google Scholar
  16. 16.
    Gabrilove JL, Cleeland CS, Livingston RB, et al.: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001, 19:2875–2882.PubMedGoogle Scholar
  17. 17.
    Henry DH: Optimizing the treatment of anemia in cancer patients: the role of a new erythropoietic agent. Oncology (Huntingt) 2002, 16(Suppl 11):9–12.Google Scholar
  18. 18.
    Egrie JC, Browne JK: Development and characterization of darbepoetin alfa. Oncology (Huntingt) 2002, 16(Suppl 11):13–22.Google Scholar
  19. 19.
    Vansteenkiste J, Pirker R, Massuti B, et al.: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002, 94:1211–1220.PubMedGoogle Scholar
  20. 20.
    Hedenus, M, Adriansson M, San Miguel J, et al.: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003. 122:394–403.PubMedCrossRefGoogle Scholar
  21. 21.
    Smith RE Jr., Tchekmedyian NS, Chan D, et al.: A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 2003, 88:1851–1858.PubMedCrossRefGoogle Scholar
  22. 22.
    Glaspy JA, Jadeja JS, Justice G, et al.: Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002, 87:268–276.PubMedCrossRefGoogle Scholar
  23. 23.
    Glaspy JA, Jadeja JS, Justice G, et al.: A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 2003, 97:1312–1320.PubMedCrossRefGoogle Scholar
  24. 24.
    Glaspy JA, Tchekmedyian NS: Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology (Huntingt) 2002, 16(Suppl 11):23–29.Google Scholar
  25. 25.
    Mirtsching B, Charu V, Vadhan-Raj S, et al.: Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia: results of a combined analysis. Oncology (Huntingt) 2002, 16(Suppl 11):31–36.Google Scholar
  26. 26.
    Meehan K, Tchekmedyian S, Ciesla G, et al.: The burden of weekly epoetin alfa injections to patients and their caregivers [abstract]. Proc ASCO 2003, 22:2186.Google Scholar
  27. 27.
    Kotasek D, Steger G, Faught W, et al.: Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy: results of a doubleblind, placebo-controlled, randomised study. Eur J Cancer 2003, 39:2026–2034.PubMedCrossRefGoogle Scholar
  28. 28.
    Jumbe N, Yao B, Rovetti R, et al.: Clinical trial simulation of a 200-microg fixed dose of darbepoetin alfa in chemotherapyinduced anemia. Oncology (Huntingt) 2002, 16(Suppl 11):37–44.Google Scholar
  29. 29.
    Tarng DC, Huang TP, Chen TW, Yang WC: Erythropoietin hyporesponsiveness: from iron deficiency to iron overload. Kidney Int 1999, 69(Suppl):S107-S118.CrossRefGoogle Scholar
  30. 30.
    Hotta T, Ogawa H, Saito A, Ito A: Iron balance following recombinant human erythropoietin therapy for anemia associated with chronic renal failure. Int J Hematol 1991, 54:195–200.PubMedGoogle Scholar
  31. 31.
    Goodnough LT, Skikne B, Brugnara C: Erythropoietin, iron, and erythropoiesis. Blood 2000, 96:823–833. Interesting and provocative review about the interaction between iron and erythropoietin.PubMedGoogle Scholar
  32. 32.
    Weiss G: Iron and anemia of chronic disease. Kidney Int 1999, 69(Suppl):S12-S17.CrossRefGoogle Scholar
  33. 33.
    Finch CA: Erythropoiesis, erythropoietin, and iron. Blood 1982, 60:1241–1246.PubMedGoogle Scholar
  34. 34.
    Goodnough LT: The role of iron in erythropoiesis in the absence and presence of erythropoietin therapy. Nephrol Dial Transplant 2002, 17(Suppl 5):14–18.PubMedCrossRefGoogle Scholar
  35. 35.
    Goodnough LT, Marcus RE: Erythropoiesis in patients stimulated with erythropoietin: the relevance of storage iron. Vox Sang 1998, 75:128–133.PubMedCrossRefGoogle Scholar
  36. 36.
    Price TH, Goodnough LT, Vogler WR, et al.: The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: a multicenter, randomized, double-blind, controlled trial. Transfusion 1996, 36:29–36.PubMedCrossRefGoogle Scholar
  37. 37.
    Stoves J, Inglis H, Newstead CG: A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 2001, 16:967–974.PubMedCrossRefGoogle Scholar
  38. 38.
    Olijhoek G, Megens JG, Musto P, et al.: Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial. Transfusion 2001, 41:957–963.PubMedCrossRefGoogle Scholar
  39. 39.
    Macdougall IC: Strategies for iron supplementation: oral versus intravenous. Kidney Int 1999, 69(Suppl):S61-S66.CrossRefGoogle Scholar
  40. 40.
    Fishbane S: Safety in iron management. Am J Kidney Dis 2003, 41(Suppl):18–26.PubMedCrossRefGoogle Scholar
  41. 41.
    Calvar, C., Mata D, Alonso C, Ramos B, et al.: Intravenous administration of iron gluconate during haemodialysis. Nephrol Dial Transplant 1997. 12(3):574–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Zanen AL, Adriaansen HJ, van Bommel EF, et al.: ‘Oversaturation’ of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients. Nephrol Dial Transplant 1996, 11:820–824.PubMedGoogle Scholar
  43. 43.
    Auerbach M, Barker L, Bahrain H, et al.: Intravenous iron (IV Fe) optimizes the response to erythropoietin (EPO) in patients with anemia of cancer and cancer chemotherapy: results of a multicenter, open-label, randomized trial. Blood 2001, 98(Suppl):A3323.Google Scholar
  44. 44.
    National Cancer Institute Clinical Trials PDQ. http:// Accessed April 20, 2004. The temporary closure of the GOG-191 epoetin trial due to an apparent excess of thromboembolic events in the active therapy arm is a reminder that assumptions about clinical benefit need to be verified in randomized, prospective trials.Google Scholar
  45. 45.
    Wun T, Law L, Harvey D, et al.: Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003, 98:1514–1520.PubMedCrossRefGoogle Scholar
  46. 46.
    Henke M, Laszig R, Rube C, et al.: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362:1255–1260.PubMedCrossRefGoogle Scholar
  47. 47.
    Thews O, Koenig R, Kelleher DK, et al.: Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 1998, 78:752–756.PubMedGoogle Scholar
  48. 48.
    Littlewood TJ, Bajetta E, Nortier JW, et al.: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001, 19:2865–2874.PubMedGoogle Scholar
  49. 49.
    Gershon SK, Luksenburg H, Cote TR, Braun MM: Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002, 346:1584–1586.PubMedCrossRefGoogle Scholar
  50. 50.
    Leyland-Jones B: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003, 4:459–460.PubMedCrossRefGoogle Scholar
  51. 51.
    Brand A: Immunological aspects of blood transfusions. Transpl Immunol 2002, 10:183–190.PubMedCrossRefGoogle Scholar
  52. 52.
    Shao W, Edelman LS, Sullivan DJ, et al.: Long-term cytokine alterations following allogeneic blood transfusion. J Investig Med 1998, 46:161–167.PubMedGoogle Scholar
  53. 53.
    Tartter PI: Immunologic effects of blood transfusion. Immunol Invest 1995, 24:277–288.PubMedGoogle Scholar
  54. 54.
    Santin AD, Bellone S, Parrish RS, et al.: Influence of allogeneic blood transfusion on clinical outcome during radiotherapy for cancer of the uterine cervix. Gynecol Obstet Invest 2003, 56:28–34.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • David P. Steensma
    • 1
  1. 1.Division of Hematology, Department of MedicineMayo ClinicRochesterUSA

Personalised recommendations